Pharma Pioneer

Upcoming Alzheimer's Treatments: 5 Key Data Results in 2024

29 May 2024
2 min read

Recent advancements in Alzheimer's treatment are promising, with Biogen and Eisai's Leqembi receiving full approval in July, and EliLilly's donanemab potentially following suit soon. Despite initial setbacks with Aduhelm's contentious approval, the field is progressing, with Biogen discontinuing its sales and ceasing the post-approval study. Analyst Graig Suvannavejh at Mizuho Americas anticipates a combination therapy approach, similar to cancer treatments, to be the future direction.
Here are five Alzheimer's therapeutic assets with significant potential in 2024:

AL002 by Alector/AbbVie: This monoclonal antibody targets TREM2, a receptor whose impairment is linked to dementia. AL002 is in Phase II trials, with results expected in Q4 of 2024.
Fosgonimeton by Athira Pharma: This novel therapy modulates the HGF system to activate neuroprotective pathways. Despite a setback in a Parkinson's dementia trial, a Phase II/III trial for Alzheimer's is underway with results due in H2 of this year.
ALZ-801 by Alzheon: This oral treatment aims to prevent amyloid oligomers formation. It is currently in Phase III trials, with results expected mid-year.
PRX012 by Prothena: This next-gen anti-amyloid antibody has the potential to be best-in-class and is administered subcutaneously. It is in Phase I trials, with an update expected this year.
AXS-05 by Axsome Therapeutics: A repurposed antidepressant, AXS-05 targets Alzheimer's-related agitation. A pivotal Phase III study's results are anticipated in Q2 of 2024. As of January 2023, 141 drugs across 187 trials are being evaluated for Alzheimer's, signaling an innovative and dynamic landscape for treatment options. Suvannavejh expresses enthusiasm for the future of Alzheimer's disease treatment innovation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

MariTide: Amgen's Experimental Obesity Drug Demonstrates Sustained Weight Loss in Phase I
Pharma Pioneer
2 min read
MariTide: Amgen's Experimental Obesity Drug Demonstrates Sustained Weight Loss in Phase I
29 May 2024
Phase I clinical trial results for Amgen’s experimental weight-loss drug, MariTide, indicate it may provide longer-lasting effects compared to existing glucagon-like peptide-1 (GLP-1) treatments such as Novo Nordisk’s Wegovy and EliLilly’s Zepbound.
Read →
Vividion Initiates Phase I Trial for Oral STAT3 Inhibitor in Advanced Tumors
Pharma Pioneer
2 min read
Vividion Initiates Phase I Trial for Oral STAT3 Inhibitor in Advanced Tumors
29 May 2024
Vividion Therapeutics, a subsidiary of Bayer AG, has commenced a Phase I clinical trial for VVD-130850, an oral STAT3 inhibitor intended to treat advanced solid and hematologic tumors.
Read →
Thermosome Advances to Higher Dosage in THE001 Phase I Clinical Trial
Pharma Pioneer
2 min read
Thermosome Advances to Higher Dosage in THE001 Phase I Clinical Trial
29 May 2024
Thermosome has received approval from the Data Safety Monitoring Board (DSMB) to continue with the planned dosage increase in its Phase I clinical trial for THE001.
Read →
AgenT-797 Demonstrates Potential in Treating Severe ARDS, Study in Nature Communications Reveals
Pharma Pioneer
3 min read
AgenT-797 Demonstrates Potential in Treating Severe ARDS, Study in Nature Communications Reveals
29 May 2024
MiNK Therapeutics's primary product, AGENT-797, is currently undergoing multiple Phase 1 clinical trials, with anticipated results to be released later this year.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.